Volume 18, Number 3—March 2012
Culturing Stool Specimens for Campylobacter spp., Pennsylvania, USA
Highlight and copy the desired format.
|EID||M’ikanatha NM, Dettinger LA, Perry A, Rogers P, Reynolds SM, Nachamkin I, et al. Culturing Stool Specimens for Campylobacter spp., Pennsylvania, USA. Emerg Infect Dis. 2012;18(3):484-487. https://dx.doi.org/10.3201/eid1803.111266|
|AMA||M’ikanatha NM, Dettinger LA, Perry A, et al. Culturing Stool Specimens for Campylobacter spp., Pennsylvania, USA. Emerging Infectious Diseases. 2012;18(3):484-487. doi:10.3201/eid1803.111266.|
|APA||M’ikanatha, N. M., Dettinger, L. A., Perry, A., Rogers, P., Reynolds, S. M., & Nachamkin, I. (2012). Culturing Stool Specimens for Campylobacter spp., Pennsylvania, USA. Emerging Infectious Diseases, 18(3), 484-487. https://dx.doi.org/10.3201/eid1803.111266.|
In 2010, we surveyed 176 clinical laboratories in Pennsylvania regarding stool specimen testing practices for enteropathogens, including Campylobacter spp. Most (96.3%) routinely test for Campylobacter spp. In 17 (15.7%), a stool antigen test is the sole method for diagnosis. We recommend that laboratory practice guidelines for Campylobacter spp. testing be developed.
Clinical microbiology laboratories play a critical role in surveillance for infectious diseases, including recognition of outbreaks and clarification of disease trends over time (1). Few studies have examined laboratory testing practices for common enteric pathogens, particularly Campylobacter spp., fastidious organisms that can be difficult to detect because of specimen transport and specific culture requirements (2–4). With the exception of geographic locations included in the Centers for Disease Control and Prevention’s (CDC’s) Foodborne Diseases Active Surveillance Network (5), surveillance for Campylobacter spp. is largely based on passive reporting without additional confirmation by public health laboratories.
Surveillance for Campylobacter spp. in Pennsylvania is limited, and only a fraction of isolates are submitted to the state public health laboratory because there is no regulatory requirement to do so. Because testing practices for enteric infections are not standardized (and largely unknown in Pennsylvania), understanding the methods used to diagnose enteric diseases in clinical laboratories is essential if surveillance programs are to be strengthened. We describe the results obtained from a survey conducted among clinical microbiology laboratories in Pennsylvania to assess laboratory testing practices for enteric pathogens, with an emphasis on Campylobacter diagnostics.
In November 2010, the Pennsylvania Bureau of Laboratories used an automated laboratory information system to send, by fax, a standardized questionnaire to 176 (86.6%) of the 203 clinical microbiology laboratories in Pennsylvania. The questionnaire assessed selected characteristics of stool-testing practices in calendar year 2009, the type of testing for routine stool specimen workup, use of transport media for stool samples, specimen-processing time, and specific laboratory testing practices for Campylobacter spp.
One hundred forty-nine (84.7%) laboratories responded to the survey; 144 were hospital based, 3 were reference laboratories, and 2 were public health laboratories. Hospital laboratories had, on average, 5.7 (range 0–43) full-time equivalent employees, of which 5.4 were certified by a credentialing agency, such as the American Society for Clinical Pathology, to perform clinical microbiology testing. Of the 149 responding laboratories, 107 (71.8%) tested stool specimens for enteric pathogens in house.
In Pennsylvania, all 107 laboratories included Salmonella and Shigella spp. in the routine testing protocol for enteric pathogens, and 104 (97.2%) routinely included testing for Campylobacter spp. (Table 1). Sixty-one (57.0%) laboratories included either Escherichia coli O157 cultures or culture plus stool toxin testing. Testing for Aeromonas and Plesiomonas spp. was included as routine by 57.9% and 55.1% of laboratories, respectively. Most (75.7%) stool specimens were processed within 4 hours after receipt in the laboratory, but only 43.9% of laboratories received specimens in transport media, such as Cary-Blair. Although we did not assess the time from collection of the sample to delivery in the laboratory, given the fastidious nature of Campylobacter spp., delays in stool-specimen processing might affect recovery of the organisms, especially if transport medium was not used. Of 107 laboratories in our survey, 99 (92.5%) performed fecal white cell analysis. Fecal white cell analysis has been promoted by some researchers as a useful test for triaging stool samples for culture and for enabling case management decisions (6). However, the evidence for using this test in treatment decisions is weak, at best, and it is not recommended for routine use or for decision making regarding type of pathogen or treatment (7).
In a College of American Pathologists Quality Probe (CAP Q-Probe) study conducted in 1996 (3), 96% of 601 laboratories that responded to a survey reported including Campylobacter spp. as part of the routine stool culture workup. In fact, the data on routine culture workup from the current study look remarkably similar to the data from the CAP Q-Probe survey. The CAP Q-Probe survey also showed that 33.9% of laboratories included cultures for E. coli O157. A 1999 CDC survey of stool culture practices by 388 laboratories at 9 FoodNet surveillance sites (2) found that most laboratories (97%) included Campylobacter spp. in their routine stool culture–testing procedure, but the respondents did not comment on specific laboratory testing protocols. All laboratories in the CDC survey performed cultures for Salmonella and Shigella spp.; however, only 57% of laboratories routinely tested all stool samples for E. coli O157. A CDC survey of 264 clinical laboratories at 5 FoodNet sites during 1996 found several laboratory testing differences in culturing for Salmonella spp (4).
Among laboratories in the present survey, some variation occurred in the type of culture media used for Campylobacter spp. isolation (Table 2), but most laboratories used either cefoperazone-vancomycin-amphotericin agar or Campylobacter blood agar plates (Campy-BAP). Few studies have evaluated multiple media for isolation of Campylobacter spp.; however, Arzate Barbosa et al. (8) showed that Campy-BAP was significantly less sensitive to a charcoal-containing formulation, charcoal-cefoperazone-deoxycholate agar, for isolating Campylobacter spp. Two of the laboratories in our survey reported using a charcoal-based medium, Campy charcoal-based selective medium. In a comparison of several media, Endtz et al. (9) also found that Campy-BAP was particularly insensitive for detecting C. coli isolates.
Several laboratories in our survey used enrichment media for culturing Campylobacter spp., although the value of using enrichment media still needs to be addressed (10). One laboratory reported using a CO2 atmosphere for Campylobacter culture rather than microaerobic conditions. Although this usage represents a small proportion of laboratories, suboptimal conditions for isolation of Campylobacter spp. will result in false-negative results. Whether this practice is more widespread in laboratories outside Pennsylvania is unknown.
Most laboratories used 42°C for incubating Campylobacter cultures, the optimum temperature for the most common campylobacters, mainly C. jejuni and C. coli. The incubation time before the culture is finalized was 48 hours for 64 laboratories and 72 hours for 33 laboratories. Of note, 1 laboratory incubates the culture for only 24 hours before it reports the results as negative. We also found that laboratory practices vary in performing assays to identify Campylobacter once it is isolated. Most laboratories (89.7%) used the Gram stain and oxidase test identify Campylobacter spp., but only 51 laboratories (47.7%) used the hippurate hydrolysis test to identify C. jejuni. Hippurate hydrolysis is one of the most useful and simplest methods of identifying C. jejuni without additional phenotypic testing (10). Disk identification methods were used by 21 (19.6%) laboratories, although the usefulness of these tests is limited (10). While resistance to antimicrobial drugs is a concern, particularly to fluoroquinolones (11), only 4 (3.7%) laboratories tested Campylobacter isolates for susceptibility to drugs used for treatment.
In 2009, 18 (16.8%) Pennsylvania laboratories used commercial stool specimen antigen assays for detecting Campylobacter spp., and of particular concern, 17 laboratories used these assays in lieu of culture methods. In a previous CDC survey of 388 laboratories concerning practices of stool specimen analysis during 1999, only 1 laboratory used a stool antigen test as a sole diagnostic test for Campylobacter spp (2). Taken together, these data suggest that antigen testing for Campylobacter spp. in stool specimens is increasing as a sole method for diagnosing Campylobacter infection.
Although these data represent a cross-sectional survey of the practices at the time of the survey, laboratory procedures for identifying enteric pathogens, such as Campylobacter, typically tend to be stable unless the advantages to implementing new methods are apparent. Given the trend observed, we can reasonably conclude that more laboratories may adopt antigen-detection methods other than stool culture as a means of diagnosing Campylobacter infection. A 2011 CDC study that evaluated several different Campylobacter stool antigen assays concluded, however, that the performance of stool antigen assays was insufficient as a sole diagnostic for Campylobacter spp (12). An increase in stool antigen testing for Campylobacter spp. would affect surveillance data by causing the number of cases to be underestimated because of poor testing sensitivity and may also result in hampering outbreak investigation because of the poor specificity of antigen testing. In some jurisdictions (e.g., Pennsylvania) antigen test results are excluded in criteria for the case definition for Campylobacter infections, although other public health jurisdictions include such results. Inconsistencies across states, resulting from conflicting evidence (12,13), present a challenge in interpreting data on the national level.
Standardized guidelines for testing enteric pathogens by clinical laboratories and submission of isolates to public health laboratories can enhance surveillance. For example, in 2009, CDC provided testing guidelines for clinical laboratories for E. coli O157 and Shiga toxin–producing E. coli. These guidelines recommend both antigen and culture testing of samples from patients with acute community-acquired diarrhea (14). Since then, the Pennsylvania Bureau of Laboratories has observed an increase of 48% in the number of laboratories that perform toxin antigen testing. In 2011, 32 sites submitted positive toxin broths, compared with 15 sites in 2009. The characterization of these isolates by public health laboratories has improved surveillance data in addition to enhancing outbreak investigations.
In the CDC survey of clinical laboratories, investigators noted that because almost all laboratories routinely test stool samples for Campylobacter spp., regional differences in the incidence of culture-confirmed illness were unlikely to be related to laboratory practices (2). Of all fecal pathogens, Campylobacter spp. are probably the most difficult for clinical laboratories to isolate, and we found some variation in laboratory practices for isolating these pathogens. Using different methods for testing stool specimens for Campylobacter spp. would most likely affect surveillance results. Variation in testing methods would also suggest differences in practices for handling and processing specimens, which would, in turn, affect recovery and detection of Campylobacter spp. We conclude that variation in practices likely influences surveillance-based data; however, the extent is unknown.
This study suggests that variation in laboratory practices is a potential problem in surveillance for Campylobacter spp. in Pennsylvania. Yet, the differences in laboratory practices for Campylobacter spp. are unlikely to be unique to Pennsylvania. These factors need to be considered when surveillance data are interpreted and laboratory training programs are devised. Our study also suggests that laboratory practice guidelines for Campylobacter testing should be developed.
Dr M’ikanatha is an epidemiologist at the Pennsylvania Department of Health. He is engaged in efforts to enhance surveillance for infectious diseases, including collaborative efforts to monitor antimicrobial drug resistance in enteric pathogens of animal origin.
This study was supported in part by the Agency for Healthcare Research and Quality Centers for Education and Research on Therapeutics cooperative agreement (U18-HS10399) and by the Pennsylvania Department of Health through the Centers for Disease Control and Prevention grant (ELC-04040) for National Antimicrobial Resistance Monitoring.
- Thacker SB, Berkelman RL. Public health surveillance in the United States. Epidemiol Rev. 1988;10:164–90.
- Voetsch AC, Angulo FJ, Rabatsky-Ehr T, Shallow S, Cassidy M, Thomas SM, Laboratory practices for stool-specimen culture for bacterial pathogens, including Escherichia coli O157:H7, in the FoodNet sites, 1995–2000. Clin Infect Dis. 2004;38(Suppl 3):S190–7.
- Valenstein P, Pfaller M, Yungbluth M. The use and abuse of routine stool microbiology: a college of American pathologists Q-probes study of 601 institutions. Arch Pathol Lab Med. 1996;120:206–11.
- Voetsch AC, Van Gilder TJ, Angulo FJ, Farley MM, Shallow S, Marcus R, FoodNet estimate of the burden of illness caused by nontyphoidal Salmonella infections in the United States. Clin Infect Dis. 2004;38(Suppl 3):S127–34.
- Centers for Disease Control and Prevention. Foodborne Diseases Active Surveillance Network. [cited 2011 Jul 6]. http://www.cdc.gov/foodnet/
- Thielman NM, Guerrant RL. Acute infectious diarrhea. N Engl J Med. 2004;350:38–47.
- Hines J, Nachamkin I. Effective use of the clinical microbiology laboratory for diagnosing diarrheal diseases. Clin Infect Dis. 1996;23:1292–301.
- Arzate Barbosa P, Gonzalez RG, Nava EP, Nachamkin I. Comparison of two selective media for the isolation of Campylobacter species from a pediatric population in Mexico. Diagn Microbiol Infect Dis. 1999;34:329–32.
- Endtz HP, Ruijs GJHM, Zwinderman AH, van der Reijden T, Biever M. Mouton, RP. Comparison of six media, including a semisolid agar, for the isolation of various Campylobacter species from stool specimens. J Clin Microbiol. 1991;29:1007–10.
- Fitzgerald C, Nachamkin I. Campylobacter and Arcobacter. In: Versalovic J, Carroll KC, Funke, G, Jorgensen JH, Landry M, Warnock DW, editors. Manual of clinical microbiology. Washington: ASM Press; 2011.p. 885–99.
- Vlieghe ER, Jacobs JA, Van Esbroeck M, Koole O, Van Gompel A. Trends of norfloxacin and erythromycin resistance of Campylobacter jejuni/Campylobacter coli recovered from international travelers, 1994 to 2006. J Travel Med. 2008;15:419–25.
- Fitzgerald C, Gonzalez A, Gillim-Ross L, Hurd S, DeMartino M, Razeq J, Multicenter study to evaluate diagnostic methods for detection and isolation of Campylobacter from stool. In: Abstracts of the 111th annual meeting of the American Society for Microbiology, New Orleans, Louisiana, 2011. Washington: ASM Press; 2011.
- Granato PA, Chen L, Holiday I, Rawling RA, Novak-Weekley SM, Quinian T, Comparison of premier CAMPY enzyme immunoassay (EIA), ProSpecT Campylobacter EIA, and ImmunoCard STAT! CAMPY tests with culture for laboratory diagnosis of Campylobacter enteric infections. J Clin Microbiol. 2010;48:4022–7.
- Gould LH, Bopp C, Strockbine N, Atkinson R, Baselski V, Body B, Recommendations for diagnosis of Shiga toxin–producing Escherichia coli infections by clinical laboratories. MMWR Recomm Rep. 2009;58(RR-12):1–14.
- Table 1. General laboratory practices for 107 Pennsylvania laboratories performing testing of stool specimens, 2009
- Table 2. Campylobacter-specific laboratory practices for 107 Pennsylvania laboratories performing testing of stool specimens, 2009
Please use the form below to submit correspondence to the authors or contact them at the following address:
Irving Nachamkin, Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Founders 7-046, 3400 Spruce St, Philadelphia, PA 19104-4283, USA
Comment submitted successfully, thank you for your feedback.
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
- Page created: February 16, 2012
- Page last updated: February 16, 2012
- Page last reviewed: February 16, 2012
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)